在非糖尿病疾病中治疗内皮功能障碍的甲福明:一个范围审查
Roland van Rensburg1, Anel Schoonees2, Mohammed W Ali3
1Division of Clinical Pharmacology, Department of Medicine, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, South Africa rvr@sun.ac.za.
BMJ open
|October 7, 2025
概括
梅特福林在非糖尿病情况下显示出改善内皮功能障碍的潜力,但需要更多的研究. 本范围审查强调了生物标志物选择和对甲胺的多样化人口研究中的知识差距.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- 降血糖药物梅特福明显示出超出糖尿病范围的潜在益处,特别是改善内皮功能障碍.
- 现有的关于甲福明对非糖尿病患者内皮功能障碍的影响的文献缺乏全面的综合.
- 内皮功能障碍是各种非传染性疾病 (NCD) 的关键因素.
研究的目的:
- 绘制关于在非糖尿病NCD中治疗内皮功能障碍的甲福明的研究范围和性质的地图.
- 在涉及甲胺的研究中识别用于测量内皮功能障碍的生物标志物.
- 识别当前研究领域的知识缺口.
主要方法:
- 根据既定的方法框架 (Arksey和O'Malley,Joanna Briggs研究所) 进行了范围审查.
- 包括对成年人使用甲福明治疗非糖尿病非传染性疾病中的内皮功能障碍的同行评审研究.
- 不包括叙述性评论,专家意见,临床前和定性研究. 进行了广泛的数据库搜索.
主要成果:
- 确定了56项涉及4620名参与者的研究,卵巢多囊综合征是研究最多的非传染性疾病.
- 观察了内皮功能障碍的19种不同的生物标志物,流介导扩张是最常见的.
- 甲胺在36.8%的生物标志物中显示出改善的趋势,但在没有活性对比剂的研究中,显著差异更为明显.
结论:
- 越来越多的证据支持在非糖尿病非传染性疾病中治疗内皮功能障碍的方法,但知识差距仍然存在.
- 对于最佳的生物标志物选择,剂量策略和在更广泛的非传染性疾病 (NCDs) 中的应用,包括艾滋病毒感染者,需要进一步的研究.
- 需要进行强有力的初级和二级研究,以量化甲胺对内皮功能障碍的精确影响.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
583
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
583
Diabetes: Management and Pharmacotherapy
867
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
867
Dipeptidyl Peptidase 4 Inhibitors
587
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
587
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Diabetes Mellitus: Overview and Type I Subtype
4.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.9K
Oral Hypoglycemic Agents: Glinides
598
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
598


